- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
APO-Cefuroxime, Ceftin, PRO-Cefuroxime
Synonyms :
Class :
Antibiotics & Cephalosporins (second generation)
Dosage forms & Strengths
Suspension, Oral:
125 mg (5 ml)
250 mg (5 ml)
Solution reconstituted, IV,IM:
750 mg
1.5 mg
7.5 mg
75 mg
22 mg
Tablet, Oral:
250 mg
500 mg
Note: Oral suspensions of cefuroxime such as ceftin has been discontinued in the US.
Wound infection (animal or human):
500 mg oral b.i.s in combination with other beta-lactamase inhibitors for 5 to 14 days (duration of therapy based on the clinical response)
Chronic obstructive pulmonary disease (COPD):
500 mg oral b.i.s for 5 to 7 days
Acute Cholecystitis, perforated appendix, diverticulitis, and other intra-abdominal infections:
1.5 g IV every 8 hours in combination with metronidazole for 5 to 10 days;
For uncomplicated appendicitis, the duration is 7 to 10 days
Lyme disease:
500 mg oral b.i.s for 14 days
Acute otitis media:
500 mg oral b.i.s for 5 to 7 days (for severe infections 10 days)
Pneumonia:
500 mg oral b.i.s in combination with other antibiotics for 5 days
Pharyngitis:
250 mg oral b.i.s for 10 days
Surgical prophylaxis:
1.5 g IV in combination with metronidazole within 60 minutes prior to surgery
(Repeat the dose in 4 hours for lengthy surgery)
Urinary tract infection:
250 mg b.i.s daily for 5 to 7 days
Dose adjustments:
Dose adjustments for oral route:
Dose adjustment for IV route:
Dosage forms & Strengths
Suspension, Oral:
125 mg (5 ml)
250 mg (5 ml)
Solution reconstituted, IV, IM:
750 mg
1.5 mg
7.5 mg
75 mg
22 mg
Tablet, Oral:
250 mg
500 mg
Note: Ceftin (oral suspension) has been discontinued in the US.
General dosing for infants, children, and adolescents:
Mild to moderate infection:
20 to 30 mg/kg oral divided twice a day (do not exceed 500mg/dose)
75 to 100 mg/kg IV/IM split into three doses (do not exceed 1500mg/dose)
100 to 200 mg/kg IV/IM split into 3 or 4 doses for severe infections (do not exceed 1500mg/dose)
Bone & joint infection:
50 mg/kg IV/IM per dose q8H (do not exceed 1,500 mg/dose), follow up with antibiotic dose if indicated
Bronchitis:
250 mg to 500 mg oral tablet q12H continued for 10 days
Impetigo:
15 mg/kg oral suspension twice a day for 10 days (do not exceed 500mg/dose)
Pharyngitis:
10 mg/kg oral suspension twice a day (do not exceed 250mg/dose)
Intra-abdominal infection:
4500 mg IV per day divided equally for a single dose administered every 6 hours (do not exceed 1500mg/dose)
Sinusitis:
For infants >3 months and children: 15 mg/kg oral suspension twice a day for 10 days (do not exceed 500 mg/dose)
Adolescents: 250 to 500 mg oral tablet twice a day for 10 days
Skin and skin structure infections:
250 to 500 mg oral tablet twice a day for 10 days
Surgical prophylaxis:
50 mg/kg within 60 minutes prior to proceeding for surgery, repeat the dose in 4 hours for lengthy or complicated surgery
Refer to adult dosing
cefuroxime: they may diminish the serum concentration of antacids
cefuroxime: they may diminish the serum concentration of antacids
cefuroxime: they may diminish the serum concentration of antacids
cefuroxime: they may diminish the serum concentration of antacids
cefuroxime: they may diminish the serum concentration of antacids
the interaction decreases the therapeutic effects of the vaccine
the interaction decreases the therapeutic effects of the vaccine
the interaction decreases the therapeutic effects of the vaccine
bazedoxifene conjugated estrogens
cefuroxime may reduce the therapeutic effects of oral forms of conjugated estrogen by altering gut microflora
cefuroxime will reduce the therapeutic effects of oral forms of hormones by altering gut microflora
cefuroxime will reduce the therapeutic effects of oral forms of hormones by altering gut microflora
furosemide may enhance the therapeutic effects of cefuroxime
the interaction may increase the therapeutic effects of cefuroxime
the interaction may increase the therapeutic effects of cefuroxime
cefuroxime reduces the therapeutic effects of sodium picosulfate by altering metabolism
cephalosporins may decrease serum concentration and enhance nephrotoxicity of aminoglycosides
enhance the serum drug concentration by reducing renal clearance
enhance the serum drug concentration by reducing renal clearance
may raise the risk of nephrotoxicity
cefuroxime increases the anticoagulant activity of warfarin by an unknown mechanism
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may increase the nephrotoxic effect of aminoglycosides
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
may enhance the anticoagulant effect of Vitamin K antagonists
When both drugs are combined, there may be an increased risk or severity of adverse effects
demeclocycline reduces the effects of bactericidal agents
doxycycline reduces the effects of bactericidal agents
cefuroxime increases the serum concentration of other drugs by reducing renal clearance
cefuroxime increases the serum concentration of other drugs by reducing renal clearance
cefuroxime increases the serum concentration of other drugs by reducing renal clearance
the interaction reduces the effects of cefuroxime
cefuroxime increases the therapeutic effects of cyclopenthiazide
cefuroxime increases the serum concentration of other drugs by reducing renal clearance
cefuroxime will increase the effects of sulfasalazine
Frequency defined:
1-10%
Diarrhea (3%)
Nausea (2%)
Vomiting (7%)
Headache (1%)
Fever
Pruritis localized (1%)
Skin rash (1%)
Increase serum aspartate aminotransferase (2%)
Eosinophilia (3%)
Jarisch-herxheimer reaction (6%)
<1%:
Chest pain
Increased thirst
Abdominal pain
Local pain
Local inflammation
Vaginitis
Urticaria
Increased serum bilirubin
Increased serum creatinine
Anemia
Postmarketing: (rare )
Status epilepticus
Coma
Hallucination
confusion
Pregnancy consideration: Cefuroxime is assigned under pregnancy category A. cefuroxime can be considered for the treatment of maternal infection.
Lactation: Cefuroxime can be excreted in breast milk. Monitor infants for GI disturbances such as diarrhea or thrush.
Pregnancy category:
Patient information leaflet
Generic Name: Cefuroxime
Pronounced: ce· fur· o· xime
Why do we use cefuroxime?
Cefuroxime is a second-generation cephalosporin antibiotic drug. It is used to treat bacterial infections such as lung, skin, urinary tract, and kidney infections. It kills bacteria by inhibiting bacterial cell wall synthesis.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
